Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Neuronal pentraxin 2 (NPTX2)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Inflammation
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Brain and CSF levels of NPTX2 were reduced in patients with AD. Furthermore, higher baseline NPTX2 levels corresponded to less medial temporal lobe atrophy and levels of NPTX2 are correlated with cognition.

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Johns Hopkins University School of Medicine;Eunice Kennedy-Shriver National Institute of Child Health and Human Development; National Institute on Aging, Intramural Research Program; University of California San Diego Medical Center,Shiley-Marcos Alzheimer’s Disease Research Center, University of California San Diego Medical Center; Institute for Basic Research, New York City; Columbia University; University of California, San Francisco; University of Kentucky; Iowa State University; Aging Mind and Brain Institute, University of Iowa; Alzheimer’s Disease Neuroimaging Initiative

  1. Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2017). Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease. The FASEB Journal, 32(2), 888-893. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888398/

  2. Swanson, A., Willette, A. A., & Alzheimer’s Disease Neuroimaging Initiative. (2016). Neuronal pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer’s disease spectrum. Brain, behavior, and immunity, 58, 201-208. https://www.ncbi.nlm.nih.gov/pubmed/27444967

  3. Willette, A. A. (2015). Novel inflammatory CSF biomarkers strongly predict medial temporal atrophy and cognitive decline in Alzheimer’s disease. Brain, Behavior, and Immunity, 49, e22. https://www.sciencedirect.com/science/article/pii/S0889159115003116

  4. Xiao, M. F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C. C., Shi, Y., ... & Brewer, J. (2017). NPTX2 and cognitive dysfunction in Alzheimer’s Disease. Elife, 6, e23798. https://www.ncbi.nlm.nih.gov/pubmed/28440221